Tumor-associated neutrophils in cancer: going pro

L Wu, S Saxena, M Awaji, RK Singh - Cancers, 2019 - mdpi.com
The progression of cancer is not only about the tumor cell itself, but also about other
involved players including cancer cell recruited immune cells, their released pro …

Neutrophils in the tumor microenvironment

L Wu, S Saxena, RK Singh - Tumor Microenvironment: Hematopoietic …, 2020 - Springer
Neutrophils are the first responders to inflammation, infection, and injury. As one of the most
abundant leukocytes in the immune system, neutrophils play an essential role in cancer …

Oncostatin M is a biomarker of diagnosis, worse disease prognosis, and therapeutic nonresponse in inflammatory bowel disease

S Verstockt, B Verstockt, K Machiels… - Inflammatory bowel …, 2021 - academic.oup.com
Abstract Background Oncostatin M (OSM) has been implicated in the pathogenesis of
inflammatory bowel disease (IBD) and as a marker for nonresponsiveness to anti-tumor …

Cancer stem cell plasticity drives therapeutic resistance

MR Doherty, JM Smigiel, DJ Junk, MW Jackson - Cancers, 2016 - mdpi.com
The connection between epithelial-mesenchymal (EM) plasticity and cancer stem cell (CSC)
properties has been paradigm-shifting, linking tumor cell invasion and metastasis with …

Oncostatin M: A mysterious cytokine in cancers

A Masjedi, F Hajizadeh, FB Dargani, B Beyzai… - International …, 2021 - Elsevier
Oncostatin M (OSM), as a member of the Interleukin-6 family cytokines, plays a significant
role in inflammation, autoimmunity, and cancers. It is mainly secreted by T lymphocytes …

The clinical relevance of OSM in inflammatory diseases: a comprehensive review

CL Wolf, C Pruett, D Lighter, CL Jorcyk - Frontiers in Immunology, 2023 - frontiersin.org
Oncostatin M (OSM) is a pleiotropic cytokine involved in a variety of inflammatory responses
such as wound healing, liver regeneration, and bone remodeling. As a member of the …

Oncostatin M as a new diagnostic, prognostic and therapeutic target in inflammatory bowel disease (IBD)

S Verstockt, B Verstockt, S Vermeire - Expert Opinion on …, 2019 - Taylor & Francis
Introduction: Given the high rate of primary and acquired resistance to current inflammatory
bowel disease (IBD) treatments, novel drug targets and biomarkers that aid in therapeutic …

Oncostatin M: From intracellular signaling to therapeutic targets in liver cancer

A Caligiuri, S Gitto, G Lori, F Marra, M Parola… - Cancers, 2022 - mdpi.com
Simple Summary Pro-inflammatory cytokines play a key role in innate-and adaptive-
immunity-mediated liver carcinogenesis. Among these, oncostatin M (OSM) critically …

Label-free electrochemical biosensor for direct detection of Oncostatin M (OSM) inflammatory bowel diseases (IBD) biomarker in human serum

E Sciurti, MA Signore, L Velardi, R Di Corato, L Blasi… - Talanta, 2024 - Elsevier
Oncostatin M (OSM) is an interleukin-6 (IL-6) member family cytokine implicated in the
pathogenesis of chronic diseases including inflammatory bowel disease (IBD). OSM is a …

STAT3-mediated SMAD3 activation underlies Oncostatin M-induced Senescence

BL Bryson, DJ Junk, R Cipriano, MW Jackson - Cell Cycle, 2017 - Taylor & Francis
Cytokines in the developing tumor microenvironment (TME) can drive transformation and
subsequent progression toward metastasis. Elevated levels of the Interleukin-6 (IL-6) family …